Abstract
Despite the significantly unfavourable prognosis of patients with pancreatic carcinoma and despite all the limitations, chemotherapy in palliative, adjuvant, and also in a neoadjuvant setting, represents yet an irreplaceable modality. The choice of a suitable protocol requires a careful consideration and instruction of the patient.
It helps to prolong the time to recurrence, progression, and overall survival.